The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Nun	nber) Previous Names	None	Entity Type
0001261249	Levotech, Ir	10.	X Corporation
Name of Issue			Limited Partnership
AGILE THERAPEUTICS IN	NC		Limited Liability Company
Jurisdiction o	f		General Partnership
Incorporation/Organ	nization		Business Trust
DELAWARE			Other (Specify)
Year of Incorpora	tion/Organization		
X Over Five Years Ago			
Within Last Five Years (S	pecify Year)		
Yet to Be Formed			
2. Principal Place of Business	s and Contact Information		
	of Issuer		
AGILE THERAPEUTICS IN			
	Address 1	St	reet Address 2
366 WALL STREET			
City	State/Province/Country		
PRINCETON	NEW JERSEY	08540-1715	609-683-1880
3. Related Persons			
Last Name		st Name	Middle Name
Rossi	Thomas	М.	
Street Address 1		Address 2	
c/o Agile Therapeutics, Inc.	366 Wall Street		
City		vince/Country	ZIP/PostalCode
Princeton	NEW JERSEY		40-1715
Relationship: X Executive (Officer X Director Promot	ter	
Clarification of Response (if	Necessary):		
Last Name	Fir	st Name	Middle Name
Altomari	Al		
Street Address 1	Street	Address 2	
8 Yeger Drive			
City	State/Pro	vince/Country	ZIP/PostalCode
Lawrenceville	NEW JERSEY	086	

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	Last Name First Name Middle Name	
Hong	Karen	
Street Address 1	Street Address 2	
c/o ProQuest Investments	90 Nassau Street, 5th Floor	
City	State/Province/Country	ZIP/PostalCode
Princeton	NEW JERSEY	08542
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Pellegrini	Lorenzo	
Street Address 1	Street Address 2	
c/o Care Capital Investments III LP	47 Hulfish Street, Suite 310	
City	State/Province/Country	ZIP/PostalCode
Princeton	NEW MEXICO	08542
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessar	y):	
Last Name	First Name	Middle Name
Lele	Abhijeet	
Street Address 1	Street Address 2	
630 Fifth Avenue	Suite 1965	
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10111
Relationship: Executive Officer X	Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investing Pooled Investment Fund Is the issuer registered as an investment Company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining	Health Care Biotechnology Health Insurance Hospitals & Physicians X Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel
Coal Mining Electric Utilities		

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
X No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	Rule 505 X Rule 506 Securities Act Investment Co Section 3(c)(Section 3	ompany Act Section 3(c) 1) Section 3(c)(9) 2) Section 3(c)(10) 3) Section 3(c)(11) 4) Section 3(c)(12) 5) Section 3(c)(13) 6) Section 3(c)(14)	
7. Type of Filing			
X New Notice Date of First Sale 2010-05-25 Amendment	First Sale Yet to	Occur	
8. Duration of Offering			
Does the Issuer intend this offering to last more	than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that a	pply)		
X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)	
10. Business Combination Transaction			
Is this offering being made in connection with a a merger, acquisition or exchange offer?	business combinat	tion transaction, such as Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside	e investor \$0 USD		
12. Sales Compensation			

Recipient

(Associated) Broker or Dea	aler X None		(Associated) Broker or Dealer CRD Nu	umber X None
Street	Address 1		Street Address 2	
City		f	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (sele Check "All States" or chec	11 2/	All States	Foreign/non-US	
13. Offering and Sales Amo	unts			
Total Offering Amount	\$45,010,660 USD or	r Indefini	ite	
Total Amount Sold	\$23,344,028 USD			
Total Remaining to be Sold	\$21,666,632 USD or	r Indefini	ite	
Clarification of Response (in	f Necessary):			

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

ify as 11

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AGILE THERAPEUTICS INC	Thomas M. Rossi	Thomas M. Rossi	President and Chief Executive Officer	2010-06-07

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.